Adaptive Biotechnologies (ADPT) Q4 2025 earnings review
Profitability Inflection Point Reached
Adaptive Biotechnologies delivered a pivotal quarter, proving its core business can scale profitably. Q4 Revenue jumped 51% YoY to $71.7M, but the real headline is the bottom line: Adjusted EBITDA flipped to positive $4.1M from a $16.4M loss a year ago. The Minimal Residual Disease (MRD) segment is the undisputed engine, growing 54% and carrying the company as the Immune Medicine segment restructures following the Genentech termination. Management enters 2026 with a simplified narrative focused entirely on MRD growth and sustained cash generation.
🐂 Bull Case
The scalable nature of the clonoSEQ platform is finally visible. While MRD revenue grew 54% YoY in Q4, total operating expenses only increased 4%. This gap drove the swing to positive EBITDA and cash flow.
clonoSEQ test volumes accelerated to 43% YoY growth (30,038 tests), up from 37% in Q2 and 38% in Q3. Adoption is deepening in both academic and community settings, aided by new EMR integrations.
🐻 Bear Case
With the Genentech partnership terminated and no revenue guidance provided for Immune Medicine in 2026, this segment has become a 'black box' for investors. It generated $9.8M in Q4, but future contributions are uncertain.
While growing, the company has previously noted emerging competition in the DLBCL (Diffuse Large B-Cell Lymphoma) indication. As Adaptive pushes further into community settings, maintaining market share against lower-cost or simpler alternatives remains a risk.
⚖️ Verdict: 🟢🟢
Bullish. Adaptive has successfully executed a difficult transition from 'cash burn' science project to a profitable commercial diagnostics company. The 54% growth in its core MRD business combined with fixed-cost discipline makes the financial trajectory highly attractive.
Key Themes
MRD Segment Dominance
Accelerating. The MRD business (clonoSEQ) is now the singular value driver, contributing 86% of Q4 revenue. Revenue grew 54% YoY to $61.9M. The segment has achieved standalone profitability and positive cash flow, validating the long-term investment thesis. The implementation of NovaSeq X Plus is further aiding gross margins.
EMR Integration Strategy Paying Off
Stable/Positive. The integration of clonoSEQ into Flatiron Health’s OncoEMR is a critical infrastructure win, removing friction for community oncologists. Coupled with Epic integrations, this 'digital moat' is directly correlating with volume growth, as integrated accounts historically grow 2x faster than non-integrated ones.
Cost Discipline & Operating Leverage
Accelerating. Management held operating expenses essentially flat ($84.5M vs $81.3M YoY) despite massive revenue expansion. This discipline allowed the 63% jump in core revenue (ex-Genentech) to flow directly to the bottom line, proving the business does not need linear spend to grow.
Immune Medicine Strategic Reset
Reversing. The termination of the Genentech agreement (finalized in Q3 with a revenue spike) leaves the Immune Medicine segment without its primary anchor. While Q4 saw new data licensing deals with Pfizer, the lack of 2026 revenue guidance for this segment suggests it is being deprioritized or restructured, creating modeling uncertainty.
Milestone Revenue Lumpiness
Stable. Q4 results included significant pharma regulatory milestone revenue (totaling $19.5M for the full year 2025). While lucrative, these payments are non-recurring and can mask underlying trends in recurring testing revenue if not stripped out. Investors should watch the 'core' clinical volume closely.
Reimbursement Expansion
Positive. Expanded Medicare coverage for Mantle Cell Lymphoma (MCL) recurrence monitoring adds to the Total Addressable Market (TAM). Combined with strong Average Selling Price (ASP) trends ($1,310 in FY25 vs $1,117 in FY24), payer relations are a tailwind.
Other KPIs
Strong. Cash burn has moderated significantly. The company ended the year with a robust balance sheet, sufficient to reach sustained profitability without immediate need for dilutive financing.
Accelerating. Up 43% YoY. This is the heartbeat of the company. The sequential growth from ~27k in Q3 to 30k in Q4 indicates no seasonality slowdown, a common risk in Q4 diagnostics.
Reversing (Positive). A massive swing from a loss of $80.4 million in FY24. Even excluding the one-time Genentech boost, the underlying trajectory improved by over $60 million year-over-year.
Guidance
Decelerating. The midpoint implies ~22% growth over FY25 MRD revenue of $212.3M. This is a slowdown from the blistering 46% growth seen in FY25. However, this may be conservative given the 43% volume growth exiting Q4.
Stable. Represents a slight increase (~4-7%) from FY25 expenses of $334M. This confirms management plans to keep cost controls tight while revenues grow ~20%+, driving further margin expansion.
Concern. The omission of guidance for this segment implies it is either insignificant to the financial model or too volatile to predict following the Genentech exit.
Key Questions
Conservative MRD Guidance?
FY25 MRD revenue grew 46% and Q4 volume grew 43%. Why does FY26 guidance ($255-$265M) imply a deceleration to ~22% growth? Are you anticipating pricing pressure or a volume slowdown?
Immune Medicine Profitability
With the Genentech deal over, what is the standalone burn rate of the Immune Medicine business in 2026, and is there a strategic review underway to divest or spin off this asset?
Competition in Community Oncology
As you expand further into community settings via Flatiron, are you seeing increased pressure from lower-cost competitors or 'good enough' testing alternatives for DLBCL and CLL?
Milestone Dependencies
How much of the $255-$265M FY26 MRD guidance is comprised of pharma milestones versus recurring clinical/sequencing revenue?